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Background 
 Inflammation and fibrosis are indicative of liver regeneration 
following injury and chronic liver diseases, such as cirrhosis and 
hepatocellular carcinoma 
 The formation of new vasculature via the process of                 
angiogenesis is vital to the pathological progression of liver    
regeneration and these diseases 
 Vascular endothelial growth factor (VEGF) is the most potent 
and specific growth factor for initiating the process of             
angiogenesis 
 Bevacizumab is an antibody that binds to VEGF, inhibiting it 
from initiating angiogenesis. 
Previous Study 
Current Study 
Phase 1: Titration of antibodies to determine the dilution ratio of 
each antibody  
 VEGF antibodies:  
 Primary—Rabbit Anti-Rat VEGF / Secondary—Goat Anti-
 Rabbit conjugated with Alexa Fluor 488  
 Actin antibodies  
 Option 1: Monoclonal anti-actin antibody produced in   
 mouse conjugated with Cy3  
 Option 2: Primary—Monoclonal Anti-Actin produced in  
 mouse / Secondary—Goat Anti-Mouse conjugated with Alexa 
 Fluor 568  
Phase 2: Acquire digital images for each of the 4 groups over the 
7 days and evaluate them using Image J to determine the      local-
ization and expression level of VEGF. 
Methods 
1)Samples sectioned at a thickness of 7-8 microns and collected 
on Histobond slides 
2)Rinsed in PBS for 5 mins at room temp 
3)Fixed with 0.1% paraformaldehyde for 15 min at room temp 
4) Quenched excess paraformaldehyde with ethanolamine for 10 
min at room temp 
5)Tissue was permeabilized in chilled methanol and incubated for 
5 min at -20˚C 
6)Washed 5 mins then blocked with 1% BSA, 1% inactivated 
FCS, and 0.3M glycine in PBS for 30 min at room temp 
7)Incubated with primary antibodies diluted in 1% BSA, 1%      
inactivated FCS block overnight at 4˚C 
8)Washed 3 times in PBS for 15min/wash 
9)Incubated with secondary antibody, diluted in 1% BSA, 1%    
inactivated FCS block, that was filtered with a 0.45 micron filter 
for 2-3 hours at room temp  
10)Washed 3 times in PBS 
11)Coverslips were mounted using Prolong Gold Antifade media 
with DAPI and sealed with clear nail polish 
Future Studies  
Quantitative Reverse Transcription Polymerase Chain Reaction 
assay will be used to determine gene expression of VEGF for each 
of the four groups over the 7 days.  
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Results 
Figure 3: Sham+Saline sample 1 day post-surgery was used for optimization. Image acquisition was performed using Simple PCI and exposure duration was 
kept consistent for each fluorophore as follows: DAPI at 0.4 sec, Alexa Fluor 488 at 6.0 sec, Alexa Fluor 568 at 1.0 sec, and Cy3 at 0.55 sec. 
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Figure 1:  Flow chart of surgeries and injections 
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1 2 3 4 5 6 7 
1 7489.255 ± 0.85 
2 11511.96 ± 0.89 
3 10603.53 ± 0.81 
4 14345.86 ± 0.78 
5 8431.648 ± 0.80 
6 14345.86 ± 1.05 
7 9579.99 ± 1.10 
1 14753.62 ± 1.67 
2 5136.669 ± 0.40 
3 2374.841 ± 0.18 
4 1275.991 ± 0.07 
5 2997.79 ± 0.28 
6 2898.43 ± 0.21 
7 1826.79 ± 0.21 
1 5211.054 ± 0.59 
2 19350.59 ± 1.50 
3 11226.42 ± 0.86 
4 10105.49 ± 0.55 
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6 6148.054 ± 0.45 
7 150.192 ± 0.02 
1 13337.45 ± 1.51 
2 8407.10 ± 0.65 
3 6831.347 ± 0.52 
4 2004.57 ± 0.11 
5 3497.33 ± 0.33 
6 1846.40 ± 0.13 
7 122.78 ± 0.01 
Peak Area 
Figure 2: Image J densitometry analysis of Western Blots for all treatments, normalized to the 
nitrocellulose protein expression. The areas under the peak are displayed right of the figures and 
are measured in pixels. 
